[ Expanded Access Programs ]
[ Named Patient Process ]
[ Clinical Science Liaison ]
[ and Patient Support ]
OrphanDC offers Expanded Access Programs to support Patients with a pathway to innovative investigational drugs outside of the clinical trial setting. The program provides the sponsor with real-world data, helping to manage risk when pre-launching the product, and building relationships with both patients & the medical community.
OrphanDC has an active Compassionate Use Program
for Oncology Patients
OrphanDC provides patients and physicians, in Brazil, with the opportunity to access medicines, commercially approved abroad, in their own country. Named Patient Process, aka Named Patient Sale is viable and a soft-landing opportunity in both territories.
Particularities in Brazil
9 to 12 months – market access forecast
75% – market acceptance forecast
Clinical Science Liaison
and Patient Support
Professionals with vast experience in different healthcare areas represent OrphanDC’s Clinical Science & Patient Support area. We develop and implement strategic activities related to our clients’ projects and needs.